497 related articles for article (PubMed ID: 18008338)
21. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma.
Kleinberg L; Dong HP; Holth A; Risberg B; Trope' CG; Nesland JM; Flørenes VA; Davidson B
Hum Pathol; 2009 Jun; 40(6):795-806. PubMed ID: 19157506
[TBL] [Abstract][Full Text] [Related]
22. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
23. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions.
Elstrand MB; Stavnes HT; Tropé CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):529-35. PubMed ID: 21864883
[TBL] [Abstract][Full Text] [Related]
24. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
25. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
26. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
Davidson B; Zhang Z; Kleinberg L; Li M; Flørenes VA; Wang TL; Shih IeM
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5944-50. PubMed ID: 17062665
[TBL] [Abstract][Full Text] [Related]
27. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival.
Kleinberg L; Holth A; Trope CG; Reich R; Davidson B
Hum Pathol; 2008 May; 39(5):747-57. PubMed ID: 18439941
[TBL] [Abstract][Full Text] [Related]
28. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic role of claudins in serous effusions.
Kleinberg L; Holth A; Fridman E; Schwartz I; Shih IeM; Davidson B
Am J Clin Pathol; 2007 Jun; 127(6):928-37. PubMed ID: 17509990
[TBL] [Abstract][Full Text] [Related]
30. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping.
Sigstad E; Dong HP; Nielsen S; Berner A; Davidson B; Risberg B
Diagn Cytopathol; 2005 Nov; 33(5):325-31. PubMed ID: 16240402
[TBL] [Abstract][Full Text] [Related]
31. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
32. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
Vaksman O; Davidson B; Tropé C; Reich R
Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
[TBL] [Abstract][Full Text] [Related]
33. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
34. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
[TBL] [Abstract][Full Text] [Related]
35. Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions.
Sivertsen S; Berner A; Michael CW; Bedrossian C; Davidson B
Acta Cytol; 2006; 50(6):603-7. PubMed ID: 17152269
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks.
Cho JS; Kim GE; Lee JS; Lee JH; Nam JH; Choi C
Acta Cytol; 2013; 57(4):377-83. PubMed ID: 23860190
[TBL] [Abstract][Full Text] [Related]
37. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
[TBL] [Abstract][Full Text] [Related]
38. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
[TBL] [Abstract][Full Text] [Related]
39. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
Slipicevic A; Holth A; Hellesylt E; Tropé CG; Davidson B; Flørenes VA
Gynecol Oncol; 2014 Oct; 135(1):118-24. PubMed ID: 25093290
[TBL] [Abstract][Full Text] [Related]
40. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
Davidson B; Shafat I; Risberg B; Ilan N; Trope' CG; Vlodavsky I; Reich R
Gynecol Oncol; 2007 Feb; 104(2):311-9. PubMed ID: 17030350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
